Get the Stockscreener App
1.8608
8.98%
-0.1992
Allogene Therapeutics Inc stock is traded at $1.8608, with a volume of 735.73K.
It is down -8.98% in the last 24 hours and up +32.98% over the past month.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, primarily generated from collaborations and licensing agreements, supports their research and development efforts.
See More
Previous Close:
$2.06
Open:
$2.04
24h Volume:
735.73K
Relative Volume:
0.15
Market Cap:
$420.39M
Revenue:
$95,000
Net Income/Loss:
$-327.27M
P/E Ratio:
-0.8777
EPS:
-2.12
Net Cash Flow:
$-239.25M
1W Performance:
-7.18%
1M Performance:
+32.98%
6M Performance:
-36.66%
1Y Performance:
-61.58%
1-Day Range:
$1.8609
$2.09
1-Week Range:
$1.87
$2.32
52-Week Range:
$1.32
$4.89
Allogene Therapeutics Inc Stock (ALLO) Company Profile
Name
Allogene Therapeutics Inc
Sector
Industry
Phone
(650) 457-2700
Address
210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Compare ALLO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALLO
Allogene Therapeutics Inc
|
1.87 | 420.39M | 95,000 | -327.27M | -239.25M | -2.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
501.03 | 130.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.54 | 75.53B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
579.20 | 35.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.18 | 31.72B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
250.04 | 26.76B | 3.32B | -860.46M | -1.04B | -8.32 |
Allogene Therapeutics Inc Stock (ALLO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-08-24 | Resumed | Oppenheimer | Outperform |
| May-31-24 | Initiated | Piper Sandler | Overweight |
| Jan-05-24 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-05-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Dec-08-23 | Initiated | Citigroup | Buy |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Mar-21-23 | Initiated | Bernstein | Mkt Perform |
| Jan-24-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-06-23 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-12-22 | Downgrade | BofA Securities | Buy → Underperform |
| Aug-10-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jul-15-22 | Upgrade | Goldman | Neutral → Buy |
| Jun-03-22 | Initiated | Robert W. Baird | Neutral |
| Feb-28-22 | Reiterated | B. Riley Securities | Buy |
| Oct-20-21 | Initiated | Cowen | Outperform |
| Oct-08-21 | Downgrade | Goldman | Buy → Neutral |
| Oct-08-21 | Downgrade | Stifel | Buy → Hold |
| Sep-23-21 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jun-21-21 | Resumed | Jefferies | Buy |
| May-20-21 | Upgrade | Truist | Hold → Buy |
| May-14-21 | Initiated | B. Riley Securities | Buy |
| Jan-26-21 | Upgrade | Stifel | Hold → Buy |
| Dec-10-20 | Resumed | H.C. Wainwright | Buy |
| Nov-24-20 | Initiated | BofA Securities | Buy |
| Oct-23-20 | Initiated | RBC Capital Mkts | Outperform |
| Jun-01-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| May-29-20 | Reiterated | H.C. Wainwright | Buy |
| May-19-20 | Upgrade | ROTH Capital | Neutral → Buy |
| May-15-20 | Upgrade | Guggenheim | Neutral → Buy |
| May-14-20 | Reiterated | H.C. Wainwright | Buy |
| May-14-20 | Downgrade | SunTrust | Buy → Hold |
| Apr-13-20 | Initiated | SunTrust | Buy |
| Mar-13-20 | Initiated | H.C. Wainwright | Buy |
| Mar-05-20 | Initiated | Stifel | Hold |
| Feb-24-20 | Initiated | Berenberg | Hold |
| Dec-18-19 | Initiated | JMP Securities | Mkt Outperform |
| Nov-04-19 | Initiated | Canaccord Genuity | Buy |
| Aug-09-19 | Initiated | BTIG Research | Buy |
| Jun-05-19 | Initiated | ROTH Capital | Neutral |
| May-31-19 | Initiated | Guggenheim | Neutral |
| May-23-19 | Initiated | Stifel | Hold |
| Mar-29-19 | Initiated | Piper Jaffray | Overweight |
View All
Allogene Therapeutics Inc Stock (ALLO) Latest News
Allogene Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
CAR T-cell Therapy Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 180+ Companies Working in the Domain - Yahoo Finance
Foresight Diagnostics expands Allogene partnership - BizWest
Allogene Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update - The Manila Times
When Will Allogene Reveal Its CAR T Progress? Key Earnings Date Set - StockTitan
Allogene Therapeutics Schedules Conference Call and Webcast for Q4 and Full Year 2024 Financial Results on March 13, 2025 - Nasdaq
Foresight Diagnostics Expands Strategic Partnership with Allogene Therapeutics to Advance Joint Development Activities Outside of the U.S. Across Europe, UK, Canada and Australia - The Malaysian Reserve
Allogene Short Interest Reportedly Near 5-Year Lows Amid Growing Retail Optimism: Analyst Sees CAR-T Therapy Promise - MSN
Allogene: Assessing The Pipeline, Competitive Landscape, And Opportunities (NASDAQ:ALLO) - Seeking Alpha
Allogene Expands Partnership With Foresight Diagnostics To Advance Cema-Cel Development Globally - Nasdaq
Allogene Therapeutics Announces Participation in March Investor Conference - The Manila Times
Global Advanced Therapy Medicinal Products Market to Grow Immensely at a CAGR of ~14% by 2032 | DelveInsight - The Malaysian Reserve
Allogene Therapeutics Expands Strategic Partnership with Foresight Diagnostics to Advance Joint Development Activities Outside the US Across Europe, UK, Canada, and Australia - The Manila Times
Allogene Therapeutics Expands Strategic Collaboration with Foresight Diagnostics for MRD Assay Development in Large B-Cell Lymphoma Treatment - Nasdaq
Can Allogene's $37.3M Diagnostic Partnership Transform Lymphoma Treatment Outcomes? - StockTitan
Allogene Therapeutics: Disrupting CAR-T With A Scalable Model - Seeking Alpha
Allogene Therapeutics (NASDAQ:ALLO) Sees Large Volume IncreaseWhat's Next? - MarketBeat
Allogene stock plunges to 52-week low at $1.33 amid steep annual decline - MSN
Allogene Therapeutics' SWOT analysis: CAR T pioneer's stock faces pivotal year - MSN
Insider Sell: Deborah Messemer Sells Shares of Allogene Therapeu - GuruFocus.com
Allogene therapeutics director Deborah Messemer sells $32,350 in stock - Investing.com India
Allogene Therapeutics Director Sells Shares Under Trading Plan - TradingView
Allogene therapeutics director Deborah Messemer sells $32,350 in stock By Investing.com - Investing.com UK
Watsco Posts Upbeat Results, Joins GeneDx, Intel And Other Big Stocks Moving Higher On Tuesday - Benzinga
Baird ‘encouraged’ by Allogene CAR-T therapy update - TipRanks
Optimism in War on Cancer on the Rise, as Biotech Companies Roll Out More Wins - Financial Content
Diffuse Large B-cell Lymphoma Market Expected to rise, 2034 | - openPR
Allogene stock hits 52-week low at $1.76 amid market challenges - Investing.com Nigeria
Allogene leaps on allogeneic CAR-T therapy success - The Pharma Letter
Allogene reports promising results for CAR T therapy in lymphoma - MSN
abrdn plc Invests $776,000 in Allogene Therapeutics, Inc. (NASDAQ:ALLO) - MarketBeat
Allogene Therapeutics Announces Publication of Durable - GlobeNewswire
Allogene reports promising results for CAR T therapy in lymphoma By Investing.com - Investing.com South Africa
Allogene Therapeutics Announces Positive Phase 1 Results for Cema-Cel in Treating Relapsed/Refractory Large B-Cell Lymphoma - Nasdaq
Allogene Therapeutics Announces Publication of Durable Response Data from Phase 1 ALPHA/ALPHA2 Trials of the Allogeneic CAR T Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma in the Journal of Clinical Onc - Yahoo Finance
Allogene stock plunges to 52-week low at $1.33 amid steep annual decline By Investing.com - Investing.com South Africa
A stock that deserves closer examination: Allogene Therapeutics Inc (ALLO) - US Post News
Ratio Revelations: Allogene Therapeutics Inc (ALLO)’s Financial Metrics in the Spotlight - The Dwinnex
Earl Martin Douglas Sells 6,404 Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO) Stock - MarketBeat
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Insider Sells $25,215.66 in Stock - MarketBeat
Allogene Therapeutics Inc Stock (ALLO) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.68%
0.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):